Publication: Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor
Loading...
Date
2008
Authors
Surowiak, Pawel ; Materna, Verena ; Maciejczyk, Adam ; Pudelko, Marek ; Suchocki, Slawomir ; Kedzia, Witold ; Nowak-Markwitz, Ewa ; Dumanska, Malgorzata ; Spaczynski, Marek ; Zabel, M. ; Dietel, Manfred ; Lage, Hermann
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Decreased expression of p16 may result from
hypermethylation of the promoter or from deletion of the
gene. It can lead to intensified proliferation of neoplastic
cells and to cytostatic drug resistance. The study was
aimed at the examination of prognostic value of p16
expression in relation to Ki67 and caspase-3 in ovarian
cancers using immunohistochemistry. The immunohistochemical
studies were performed on 73 paraffinembedded
samples of ovarian cancers from 43 patients
and samples from 6 healthy ovaries. We have used
monoclonal antibodies against p16. ABC method and
DAB were used for antigens visualisation. The intensity
of the immunohistochemical reactions was appraised
using the semi-quantitative IRS scale. In healthy ovaries
we have shown strong reaction in the nuclei of surface
epithelium. In the case of studied ovarian cancers, the
reaction of a nuclear and cytoplasmic localization was
obtained. The mean overall immunoreactivity score of
nuclear p16 expression amounted to 5.30±3.44 SD in
primary laparotomy material and 6.61±4.34 SD in
secondary cytoreduction material. Statistical analysis
demonstrated that lower p16 expression was typical of
the younger patients and the patients who died. Kaplan-
Meier’s analysis proved that lower expression of p16
was characteristic of cases with shorter overall survival.
In the present study we have demonstrated that lowered
p16 expression represented an unfavourable prognostic
index in ovarian cancer. Lowered p16 expression was
also typical for chemotherapy-resistant ceases (cases of
lower caspase-3 and higher Ki67 at secondary
cytoreduction expression).
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.